Article Versions Notes

De Bleser E, Willems R, Decaestecker K, Annemans L, De Bruycker A, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, et al. A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers. 2020; 12(1):132. https://doi.org/10.3390/cancers12010132

De Bleser, Elise, Ruben Willems, Karel Decaestecker, Lieven Annemans, Aurélie De Bruycker, Valérie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, and et al. 2020. "A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer" Cancers 12, no. 1: 132. https://doi.org/10.3390/cancers12010132

De Bleser, E., Willems, R., Decaestecker, K., Annemans, L., De Bruycker, A., Fonteyne, V., Lumen, N., Ameye, F., Billiet, I., Joniau, S., De Meerleer, G., Ost, P., & Bultijnck, R. (2020). A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 12(1), 132. https://doi.org/10.3390/cancers12010132